A method and system for targeting antigens unique to a tumor site. The method can include a first phase of monoclonal antibodies that bind to the tumor site. A second phase of monoclonal antibodies can be administered that bind to the first phase. A third phase of monoclonal antibodies can be administered that bind to the second phase. The third phase can include radionuclides to allow the tumor site to be imaged. Once identified, a phase of toxins can be administered, resulting in death of the tumor cells.

The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.

Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.

The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Disclosed are methods, compositions and uses of concentrated formulations of anti-CD74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (SLE). In a preferred embodiment, the anti-CD74 antibody is milatuzumab (IMMU-115). The antibody is administered subcutaneously, preferably at a dosage of 250 mg once a week for four weeks. The subcutaneous administration of anti-CD74 antibody ameliorates the symptoms of autoimmune diseases, with only manageable side effects.

Described herein are Tz/TCO-based pretargeting strategies using an Al[.sup.18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based .sup.18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, .sup.18F is more readily available to produce and therefore integrated into hospital workflows.

Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

A pharmaceutical composition comprising an immunoparticle is provided. The pharmaceutical composition comprising a monoclonal secondary antibody immunocomplexed with a primary antibody, wherein said monoclonal secondary antibody is coupled on an outer surface of a particle and wherein said particle is loaded with a pharmaceutical agent.

Provided herein, in certain aspects, are antibodies that bind to T cell receptor (TCR) Vγ9 (TRGV9), TCR Vδ2 (TRDV2), or the TCR gamma/delta constant region (TRGDC), as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.

The compositions and methods provide herein include, inter alia, antibodies attached to single-stranded oligoribonucleotides. Two antibodies are capable of forming complexes in vivo through hybridization of the respective complementary oligoribonucleotides they are bound to. For example, a first antibody bound to a first oligoribonucleotide through a first chemical linker may be administered to a subject, bind to a cell surface antigen in vivo and subsequently form an antibody complex in vivo with a second antibody bound to a second oligoribonucleotide through a second chemical linker, through complementary base-pairing between the first and the second oligoribonucleotide. The compositions and methods provided herein are, inter alia, useful for diagnostic and therapeutic purposes, for example, the treatment of cancer or autoimmune disease.